Zurück
Morphosys-Diskussion auch in USA:
http://www.siliconinvestor.com/stocktalk/subject.gsp?subject...
Ich habe schon mal versucht, mich dort anzumelden, aber das subscriben wollte nicht klappen.
Ein Nigel Bates sammelt dort die PMs auf Englisch, Diskussion ist allerdings zumeist sehr dünn, aber aktuell ist doch etwas aufgeflammt.
Lemus verhaltenes Interview mit 15% Wachstum und 20% Profit zu diesem ordentlichen aber doch geringen Wachstum sehen die user dort als extrem schlecht an. Sprechen von verwirrender IR und unheimlichen Meldungen usw.... Der Stil kommt dort nicht an.
Ach so: Die Pressemittelungen in US sind keine direkten Übersetzungen. Ich kopier mal 2 her, die Differenzen zur deutschen Version haben:
1.9.2004:
FRANKFURT (AFX) - German biotech company MorphoSys AG (Xetra: 663200.DE - news) is targeting a net profit margin of over 20 pct within the next five years, chief financial officer David Lemus told the Boersen-Zeitung newspaper.
'We want in the medium-term to perform better than the pharmaceutical industry's current average net profit margin level of 20 pct,' Lemus said.
TecDAX-aspirant MorphoSys posted a net loss of 4.1 mln eur in 2003, and Lemus said the biotech company will remain in the red this year with a loss of 1.8 mln eur.
However, 'if the second half is extremely good, it could even be the case that we will post a net profit', Lemus said.
This would be the first net profit for MorphoSys since its initial public offering in March 1999, the paper said.
MorphoSys develops therapeutic antibodies, which can be used not only for research and diagnostics but also to treat diseases.
Its three major shareholders are Cambridge Antibody Technologies Ltd with a 10.9 pct stake, Novartis AG (Virt-X: NOVN.VX - news) with 9.1 pct, and Schering AG (Xetra: 717200.DE - news) with 6.6 pct.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
8.9.2004
FRANKFURT (AFX) - German biotech company MorphoSys AG (Xetra: 663200.DE - news) is targeting at least
an average 15 pct sales growth per annum in the coming years, and is looking
to strengthen its business through acquisitions, chief financial officer Dave
Lemus told AFX News' German affiliate, dpa-AFX.
'We want to grow at least at the industry average, if not above it. Growth companies of our size should have yearly sales growth of 15
pct. This is our aim for the next few years,' Lemus said.
Lemus confirmed MorphoSys' full-year goal of 21 mln eur sales, after sales
of 15.3 mln eur in 2003. However, Lemus remained tight-lipped on when the
company will return to profit, after posting a net loss of 4.1 mln eur in 2003.
MorphoSys, which will join the TecDAX index on Sept 20, is also keeping an
eye out for acquisitions.
'We are constantly in talks. Acquisitions are a part of our strategy, and we
hope that something can be closed,' Lemus said.
This morning DSM NV (Amsterdam: DSMN.AS - news) unit DSM Biologics and Crucell NV (Amsterdam: CRCL.AS - news) announced they have
signed a research license agreement with MorphoSys.
Under the terms of the agreement, MorphoSys will receive the rights to
Crucell's human cell line technology for use in its antibody research
programmes as well as an option to a license for the clinical and commercial
production of antibodies.
Crucell and DSM Biologics will receive an upfront payment and annual
maintenance fees.
MorphoSys' three major shareholders are Cambridge Antibody Technologies Ltd
with a 10.9 pct stake, Novartis AG (Virt-X: NOVN.VX - news) with 9.1 pct, and Schering AG (Xetra: 717200.DE - news) with 6.6 pct...
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Wer ist DSM? in der Deutschen Meldung nicht erwähnt? Muss da crucell Beträge weiterleiten, und in USA muss das dann mit angegeben werden?
Und die Meldung in Deutschland war:
Finanzielle Details wurden nicht bekannt gegeben.
Hier heißt es:
Crucell and DSM Biologics will receive an upfront payment and annual
maintenance fees.
Warum diese Unterschiede von Deutsch nach Englisch? Wer weiß da was?
Hat sonst noch jemand links zu US-Diskussionsforen über Morphosys?
Grüße
ecki
http://www.siliconinvestor.com/stocktalk/subject.gsp?subject...
Ich habe schon mal versucht, mich dort anzumelden, aber das subscriben wollte nicht klappen.
Ein Nigel Bates sammelt dort die PMs auf Englisch, Diskussion ist allerdings zumeist sehr dünn, aber aktuell ist doch etwas aufgeflammt.
Lemus verhaltenes Interview mit 15% Wachstum und 20% Profit zu diesem ordentlichen aber doch geringen Wachstum sehen die user dort als extrem schlecht an. Sprechen von verwirrender IR und unheimlichen Meldungen usw.... Der Stil kommt dort nicht an.
Ach so: Die Pressemittelungen in US sind keine direkten Übersetzungen. Ich kopier mal 2 her, die Differenzen zur deutschen Version haben:
1.9.2004:
FRANKFURT (AFX) - German biotech company MorphoSys AG (Xetra: 663200.DE - news) is targeting a net profit margin of over 20 pct within the next five years, chief financial officer David Lemus told the Boersen-Zeitung newspaper.
'We want in the medium-term to perform better than the pharmaceutical industry's current average net profit margin level of 20 pct,' Lemus said.
TecDAX-aspirant MorphoSys posted a net loss of 4.1 mln eur in 2003, and Lemus said the biotech company will remain in the red this year with a loss of 1.8 mln eur.
However, 'if the second half is extremely good, it could even be the case that we will post a net profit', Lemus said.
This would be the first net profit for MorphoSys since its initial public offering in March 1999, the paper said.
MorphoSys develops therapeutic antibodies, which can be used not only for research and diagnostics but also to treat diseases.
Its three major shareholders are Cambridge Antibody Technologies Ltd with a 10.9 pct stake, Novartis AG (Virt-X: NOVN.VX - news) with 9.1 pct, and Schering AG (Xetra: 717200.DE - news) with 6.6 pct.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
8.9.2004
FRANKFURT (AFX) - German biotech company MorphoSys AG (Xetra: 663200.DE - news) is targeting at least
an average 15 pct sales growth per annum in the coming years, and is looking
to strengthen its business through acquisitions, chief financial officer Dave
Lemus told AFX News' German affiliate, dpa-AFX.
'We want to grow at least at the industry average, if not above it. Growth companies of our size should have yearly sales growth of 15
pct. This is our aim for the next few years,' Lemus said.
Lemus confirmed MorphoSys' full-year goal of 21 mln eur sales, after sales
of 15.3 mln eur in 2003. However, Lemus remained tight-lipped on when the
company will return to profit, after posting a net loss of 4.1 mln eur in 2003.
MorphoSys, which will join the TecDAX index on Sept 20, is also keeping an
eye out for acquisitions.
'We are constantly in talks. Acquisitions are a part of our strategy, and we
hope that something can be closed,' Lemus said.
This morning DSM NV (Amsterdam: DSMN.AS - news) unit DSM Biologics and Crucell NV (Amsterdam: CRCL.AS - news) announced they have
signed a research license agreement with MorphoSys.
Under the terms of the agreement, MorphoSys will receive the rights to
Crucell's human cell line technology for use in its antibody research
programmes as well as an option to a license for the clinical and commercial
production of antibodies.
Crucell and DSM Biologics will receive an upfront payment and annual
maintenance fees.
MorphoSys' three major shareholders are Cambridge Antibody Technologies Ltd
with a 10.9 pct stake, Novartis AG (Virt-X: NOVN.VX - news) with 9.1 pct, and Schering AG (Xetra: 717200.DE - news) with 6.6 pct...
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Wer ist DSM? in der Deutschen Meldung nicht erwähnt? Muss da crucell Beträge weiterleiten, und in USA muss das dann mit angegeben werden?
Und die Meldung in Deutschland war:
Finanzielle Details wurden nicht bekannt gegeben.
Hier heißt es:
Crucell and DSM Biologics will receive an upfront payment and annual
maintenance fees.
Warum diese Unterschiede von Deutsch nach Englisch? Wer weiß da was?
Hat sonst noch jemand links zu US-Diskussionsforen über Morphosys?
Grüße
ecki
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
